Publications by authors named "H J Kaufman"

Oncolytic herpes simplex viruses (oHSV) preferentially replicate in cancer cells while inducing antitumor immunity, and thus, they are often referred to as in situ cancer vaccines. OHSV infection of tumors elicits diverse host immune responses comprising both innate and adaptive components. Although the innate/adaptive immune responses primarily target the tumor, they also contribute to antiviral immunity, limiting viral replication/oncolysis.

View Article and Find Full Text PDF
Article Synopsis
  • * The study focused on JEN-101, a localized injection of interleukin-12 designed to boost immune response in dogs with advanced melanoma, evaluating its safety, effectiveness, and immune effects over several doses.
  • * Results indicated that JEN-101 was well-tolerated with manageable side effects, and it showed promising biological responses, suggesting its potential for further research and relevance to human cancer treatment.
View Article and Find Full Text PDF

Background: First-line treatment with pembrolizumab plus chemotherapy in recurrent and metastatic head and neck squamous cell carcinomas (HNSCC) has improved survival. However, the overall response rate with this standard of care regimen (SOC) remains limited. Interleukin (IL)-12 is a potent cytokine that facilitates the crosstalk between innate and adaptive immunity, making it crucial in the antitumor response.

View Article and Find Full Text PDF
Article Synopsis
  • - Talimogene laherparapvec (T-VEC) is an innovative treatment made from a modified herpes virus, approved for hard-to-treat melanoma, and this study examines genetic factors that might predict treatment success in patients.
  • - The analysis included data from 93 melanoma patients treated with T-VEC, with 30% showing complete tumor regression; key factors linked to better outcomes included early-stage disease and lack of certain metastases.
  • - Among 54 patients with available genetic data, most had gene mutations, and a specific mutation (TERT promoter) was notably linked to better clinical responses, suggesting it could influence treatment effectiveness.
View Article and Find Full Text PDF